Patients with pancreatic cancer typically develop tumor invasion and metastasis in the early stage. These malignant behaviors might be originated from cancer stem cells (CSCs), but the responsible target is less known about invisible CSCs especially for invasion and metastasis. We previously examined the proteasome activity of CSCs and constructed a real-time visualization system for human pancreatic CSCs. In the present study, we found that CSCs were highly metastatic and dominantly localized at the invading tumor margins in a liver metastasis model. Microarray and siRNA screening assays showed that doublecortin-like kinase 1 (DCLK1) was predominantly expressed with histone modification in pancreatic CSCs with invasive and metastatic potential. Overexpression of DCLK1 led to amoeboid morphology, which promotes the migration of pancreatic cancer cells. Knockdown of DCLK1 profoundly suppressed in vivo liver metastasis of pancreatic CSCs. Clinically, DCLK1 was overexpressed in the metastatic tumors in patients with pancreatic cancer. Our studies revealed that DCLK1 is essential for the invasive and metastatic properties of CSCs and may be a promising epigenetic and therapeutic target in human pancreatic cancer.
Introduction
Pancreatic cancer is the most lethal common cancer because it is usually diagnosed at an advanced stage and is resistant to therapy [1] . The overall survival rate 5 years after diagnosis is approximately 5-6%, which is the lowest rate of any cancer [2] . Despite newly devised surgical techniques and anti-cancer drugs, the treatment efficacy for pancreatic cancer has not significantly improved over the past decade due to the tendency for early invasion and metastasis [3] . These highly malignant characteristics are due to the self-renewal and differentiation of a small subpopulation of cancer cells with stem-like properties, so-called cancer stem cells (CSCs) [4, 5] , which are also referred to as metastatic stem cells [6, 7] . Recent studies revealed that the stem cell fate is determined by epigenetic mechanisms including histone modification in either normal cells [8] or CSCs [9] . More importantly, identification of molecular targets of CSCs is expected to accelerate development of novel targeted therapies [10] . Although several cell surface markers have been identified as characteristic of pancreatic CSCs [5, 11] , therapeutic targets of the invasive and metastatic process are still unclear in pancreatic cancer [12, 13] . Evaluating therapeutic strategies to target CSCs is difficult because of the complexity of reconstructing mixed populations with differentiated progeny in a hierarchical manner [14, 15] . A monitoring system based on CSC-specific functions could be one solution to these difficulties, and we utilized the low proteasome activity of CSCs to create such a system. Human breast and glioma cancer cells were engineered to stably express green fluorescence fused to the degron of ornithine decarboxylase (Gdeg), which resulted in intracellular accumulation of green fluorescent protein Gdeg as a consequence of the low activity of the 26S proteasome [16, 17] . By using this property, we previously constructed a real-time visualization system for human liver CSCs and demonstrated their high metastatic ability with niche formation [18] . Our visualization system was also used to clarify the highly malignant characteristics of human pancreatic CSCs [19] . In the present study, we identified doublecortin-like kinase 1 (DCLK1) as a protein that is predominantly expressed in invasive and metastatic CSCs. The gene was associated with epigenetics changes including H3K4me3 and H3K27me3 histone modification. DCLK1 was previously reported to be a candidate normal stem cell marker in the gut [20, 21] . However, Nakanishi et al. used lineage-tracing experiments and showed that DCLK1 marks tumor stem cells that continuously produce tumor progeny [22] . In addition, Westphalen et al. used the same strategy and reported the relationship between long-lived DCLK1-positive cells and initiation of colon cancer [23] . According to the recent report by Bailey et al., pancreatic neoplasms in mice that express DCLK1 contain morphologically and functionally distinct subpopulations with CSC-like properties [24] . Using the above visualization system and metastatic pancreatic cancers, our studies revealed that DCLK1 is highly expressed in human pancreatic CSCs and in clinical samples and may represent a therapeutic target.
Materials and Methods

Retroviral transduction of the degron reporter into human pancreatic cancer cells
The degron sequence of ornithine decarboxylase (ODC) is recognized directly by proteasomes, which leads to the immediate destruction of the involved protein [16] . The retroviral expression vector pQCXIN-ZsGreen-cODC, containing green fluorescence ZsGreen-labeled degron ODC (Gdeg), was kindly provided by Dr. Frank Pajonk (UCLA's Jonsson Comprehensive Cancer Center, CA, USA). The vector was transfected into Platinum retroviral packaging cells [25] , and the retrovirus collected from the supernatant was used to infect pancreatic cancer cells. Stable transfectants were selected with G418 (Geneticin; PROMEGA, Madison, WI, USA), and the accumulation of ZsGreen-degronODC protein (Gdeg) was monitored by fluorescence microscopy and flow cytometry (FITC channel). To verify stable transfection, the cells were exposed to the proteasome inhibitor MG-132 (Calbiochem, San Diego, CA, USA) for 12 hours. Fluorescence microscopy was performed using AxioObserver (Carl Zeiss, Oberkochen, Germany), and the images were acquired digitally using AxioVision software (Carl Zeiss).
In vitro cell migration and invasion assays
The double-chamber migration assay was performed by using a transwell chamber [26] (24-well plate, 8-μm pores; BD Biosciences, Canaan, CT, USA). For the invasion assay, 
Silencing and overexpression of DCLK1
Small interfering RNA (siRNA) targeting the candidate genes and scrambled siRNAs (siScr) not matching any human genes were purchased from Invitrogen. Freshly sorted Gdeg high cells (both KLM1 and BxPC3) were seeded at a density of 2.0 × 10 5 cells per well in 6-well plates in 2 mL culture medium. Thereafter, transfection with siRNA was performed by using RNAiMAX (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions [27] . After transfection with various concentrations (10 nM, 20 nM), the cells were incubated for 48 hours at 37°C in a 5% CO 2 atmosphere. The number of viable and nonviable cells was counted by an automatic cell counting machine by using trypan blue dye exclusion (CYTORECON; HIRATA, Tokyo, Japan). At the 48-hour time point after siRNA transfection, cells were detached from each plate to use for further experiments. The siRNA target sequences were those from high-content genomewide RNAi screens [28] . To construct the shRNA expression vector (pSilencer TM 2.1-U6 puro;
Invitrogen) [29] , KLM1-Gdeg cells (2.0 × 10 5 ) were transfected with 2.5 μg plasmid with Lipofectamine2000 (Invitrogen). The medium was changed every 2 days, and stable transfectants were isolated by incubating in medium containing 400 μg/mL puromycin. Gdeg high -BxPC3 and Gdeg low -BxPC3) were mixed with matrigel, and 100 μL was injected subcutaneously into both flanks of the mice. Tumor formation then was monitored every 4 days for up to 10 weeks. The tumor volume was estimated by using the following equation: volume = (length) × (width) 2 /2. Each group consisted of 4-6 mice. For liver metastasis analysis, the abdominal skin and muscle, approximately 5 mm in length, were incised just off the midline. The spleen was exteriorized through the incision by applying gentle traction, and the sorted cells (Gdeg high -KLM1, Gdeg low -KLM1 and Gdeg high -KLM1-shDCLK1, Gdeg high -BxPC3 and Gdeg low -BxPC3; n = 6), suspended at 1 × 10 6 cells per 100 μL PBS, were injected just under the capsule of the lower pole by using a tuberculin syringe with a 30-gauge needle. Hemostasis was obtained by applying gentle pressure (with a cotton wool swab) on the injection site. The spleen was then returned to the peritoneal cavity, and the abdomen was closed by using two 6-0 silk sutures through both skin and muscle simultaneously [30, 31] . We observed these mice for 8 weeks, and then investigated whether metastasis had occurred [32] . All in vivo procedures in this study were approved by the Animal Care Committee of Tokyo Medical and Dental University (permission No.0150044A).
Patients and samples
We 
Statistical analysis
All values are presented as the mean ± SD unless otherwise stated. The two-tailed Student's ttest (for comparison between groups) or one-way analysis of variance (for comparison of three or more groups) followed by Dunnett post-hoc tests were used for statistical analyses. SPSS software version 21.0 (SPSS, Chicago, IL) was used. Statistical significance was defined as p <0.05. (Fig 2A and 2B, 2F and 2G ). We also observed some micro-metastases in the liver of Gdeg high groups (Fig 2C and 2H ), but we note that no metastatic tumors were seen in mice injected with Gdeg low -KLM1 cells. Immunofluorescent analysis clearly revealed Gdeg high cells that were localized to the margins of the tumor (Fig 2D and 2I) . (Fig 2E and 2J ). As in a previous study [11] , our results suggested that the CSCs tended to invade further outside the tumor.
Results
Visualized pancreatic CSCs are particularly capable of liver metastasis
Overexpression of DCLK1 in association with histone modification is responsible for the invasive potential of pancreatic CSCs
To clarify the invasive and metastatic markers of pancreatic CSCs, we compared the gene expression patterns between Gdeg high cells and Gdeg low cells by microarray hybridization (S1 Data).
Scatterplot analysis of the 25,572 probes for which the detection call was "present" showed that 483 genes were upregulated and 1,138 genes were downregulated by more than 2-fold in Gdeg high -KLM1 cells compared with Gdeg low -KLM1 cells. Based on the fold change ranking in the Gdeg high cells (Table 1) , siRNA screening for candidate genes was assessed according to the inhibitory effects on Gdeg high cell migration and invasion using the double-chamber assay. Consequently, only the siRNA against DCLK1 significantly decreased cellular migration and invasion compared to controls in both KLM1 and BxPC3 Gdeg high cells (p <0.01, Fig 3A and 3B) Immunocytochemical analysis showed DCLK1 protein was mainly localized in the cytoplasm ( Fig  4A and 4B) , and reduced expression of DCLK1 was confirmed by the use of siRNA (S3 Fig, Fig  4C and 4D) . Next, we examined epigenetic aspects of DCLK1 expression by conducting chromatin immunoprecipitation (ChIP) analysis of three key histone methylation markers, H3K4me3, H3k9me3, and H3K27me3, in both Gdeg cell lines. As shown in Fig 4E , Gdeg high cells expressed higher levels of H3K4me3, which is associated with active promoters, than H3K27me3, which is associated with silenced promoters. Gdeg low cells were nearly bivalent. These results imply that DCLK1 expression in Gdeg cell lines was regulated by histone modification of H3K4 and H3K27. We found no difference in H3K9me3 levels between Gdeg high and Gdeg low in these cell lines.
DCLK1 promotes morphological changes, migration, and invasion in human pancreatic cancer cells
To investigate the role of DCLK1 in human pancreatic cancer cells, we adopted a gain-of-function strategy by using KLM1 cells that transiently over-expressed GFP-tagged DCLK1. As previously reported for neuronal cell lines, immunofluorescence analysis of KLM1-DCLK1-GFP demonstrated overlapping patterns of DCLK1 expression with microtubules by using an α-tubulin antibody [37] (Fig 5A) . The function of DCLK1 in human pancreatic cancer cells may thus be to control the action of microtubules. Movement and morphological changes including stretching pseudopodia were clearly observed in time-lapse microscopic images (Fig 5B) . During a 15-hour observation period, the migration distance of KLM1-DCLK1-GFP cells was longer than that of wild-type KLM1 cells (p <0.01, Fig 5C) . In the double-chamber assay, the number of migrating and invading KLM1-DCLK1-GFP cells was higher than that of wild-type KLM1 cells (p <0.01, Fig 5D) . Moreover, the KLM1-DCLK1-GFP cells trans-located via rapidly alternating cycles of morphological expansion and contraction called amoeboid migration (S1 Video) [38] .
DCLK1 knockdown leads to a reduction in the metastatic ability of pancreatic CSCs
To confirm the in vivo loss-of-function analysis, stable knockdown of DCLK1 was assessed in Gdeg-KLM1 cells using DCLK1 shRNA. The quality of transfection was confirmed by qRT-PCR, western blotting and immunocytochemical analyses (Fig 6A-6C ). The population of shDCLK1-Gdeg high -KLM1 cells was less than 0.5% of the total cell number (S1 Fig (n = 6). Significant liver metastases were detected following injection of control Gdeg high cells, but interestingly, no metastatic lesions were identified following injection of shDCLK1-Gdeg high cells, as determined by macroscopic and microscopic examination (Fig 6D) . These results implied that DCLK1 plays an essential role in liver metastasis in human pancreatic cancer.
Dominant expression of DCLK1 in metastatic tumors is clinically recognized in patients with pancreatic cancer
Among 135 pancreatic cancer patients who underwent surgical resection from 2005 to 2013 in our hospital, six metastatic tumors were resected synchronously or metachronously. These six pairs of primary and metastatic tumors were evaluated for the expression of DCLK1. Primary and metastatic tumors were resected synchronously in three cases, and primary tumors and metachronous distant metastases were separately resected in the other three cases (Table 2) . Interestingly, cancer cells that were positively stained for DCLK1 protein were rarely detected in the primary tumors, but were clearly detected in metastatic tumors (Fig 7A-7F) , and in all cases, the staining score was higher in metastatic tumors than in primary tumors (Fig 7G) . In cases 5 and 6 in particular, the primary tumors were completely resected and no local recurrence occurred. However, even though these patients were treated with adjuvant chemotherapy, distant metastasis appeared. In these two cases, DCLK1 expression was much higher in the metastatic tumor than in the primary tumor. These results suggest that metastatic tumors are resistant to conventional chemotherapy and that DCLK1 is a marker of metastatic tumors.
Discussion
DCLK1 consists of an N-terminus that is 65% similar to doublecortin (DCX) throughout the entire length of DCX, but DCLK1 also contains an additional 360 amino acids in the C-terminal domain, creating a putative Ca 2+ /calmodulin-dependent protein kinase. DCLK1 is located on the region of chromosome 13q13.3 [37] . The DCX gene, which is located on chromosome region Xq23, is a microtubule-associated protein required for migration of neural progenitor cells to the cerebral cortex. Mutations in DCX lead to cortical lamination defects in the developing brain that are called subcortical band heterotopia in females and classical lissencephalies in males [39] . A previous mouse study in which DCLK1 and/or DCX was knocked out revealed that both proteins have genetically compensatory roles in neuronal migration; that is, the DCLK1 gene functions in a partially redundant pathway with DCX in the formation of axonal projections across the midline and migration of cortical neurons [40] . We found that overexpressed DCLK1 promotes migration and invasion in cell lines, and knockdown suppresses these abilities. We carefully considered how our results regarding DCLK1 fit with past results regarding a neuronal role for DCLK1. Some evidence exists for the potential involvement of axon guidance genes in pancreatic carcinogenesis [41] , and these results are consistent with our finding that highly expressed DCLK1 is closely related to invasion and metastasis in pancreatic cancer. Epigenetic control of gene expression plays a major role in cell fate determination. In particular, higher-order chromatin structure is emerging as an important regulator of stem cell differentiation [8] , including even pancreatic development [42] . During the induction of pluripotency, appropriate chromatin remodeling is required for expression of stem cell-specific genes. Furthermore, several studies on brain tumors, hepatocellular carcinoma and breast cancers have shown that histone modification is responsible for the hierarchical structure that comprises cancer stem cells at the apex [43] [44] [45] . Rheinbay et al. reported the loss of H3K27me3 activates a signaling pathway required for the maintenance and tumorigenicity of glioblastoma CSCs [43] . Knockdown of H3K20 methyltransferase PR-SET7 in livers induced spontaneous development of hepatocellular carcinoma with cancer stem cell properties [44] . Westcott et al. reported an epigenetically distinct subpopulation of breast tumor cells with an enhanced capacity to collectively invade [45] . In this study, ChIP analysis revealed that the DCLK1 transcription start site in both Gdeg high cell lines was more strongly marked with histone modification for gene activation (H3K4me3) than repression (H3K27me3). These data are valuable for showing the relationship between CSCs and epigenetic regulation [46] . Why do cells that express high levels of DCLK1 show enhanced migration, invasion, and metastasis in human pancreatic ductal adenocarcinoma? In our time-lapse experiments, we found that cells with high levels of DCLK1 exhibited amoeba-like changes in morphology. The process of tumor cell invasion and metastasis is conventionally understood as the migration of individual cells that detach from the primary tumor, enter lymphatic vessels or the bloodstream, and seed in distant organs. Mesenchymal and amoeboid types of cancer cells, which are different morphological variants of cancer cells, can undergo single-cell migration [38] . Thus, we believe that the amoeboid morphology may be the reason that Gdeg high cells can invade and metastasize aggressively. Another study suggested that DCX is phosphorylated by Rho-kinase and that this phosphorylation is correlated with in vitro tumor cell migration, as well as in vivo invasion and progression [47] . However, additional details about the mechanism are unknown. Accumulating evidence has indicated pancreatic CSCs are distinguished as highly invasive and metastatic abilities [48, 49] . Hermann et al. identified a distinct subpopulation of CD133 +CXCR4+ CSCs in the invasive front of pancreatic tumors as the metastatic phenotype [11] . Our in vivo results revealed that Gdeg high cells were located at the marginal region of the metastatic tumors, and knockout of DCLK1 significantly inhibited liver metastasis. We surveyed the expression of CXCR4 with qRT-PCR, but we found no difference between Gdeg high and Gdeg low cells (data not shown). Different mechanisms may regulate invasion and metastasis by
CSCs, because these CSCs demonstrated a similar localization in the invading front of tumor margins (Fig 2D and 2I ) and indispensable potential for in vivo metastasis (Fig 6D) . Thus, the invasive and metastatic feature generally characterizes the pancreatic CSCs. Some studies implicated a relationship between DCLK1 and microRNA, especially Let-7a or miR-200a [50, 51] . They reported that DCLK1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. However, our microarray data analysis (S1 Data) identified no difference between Gdeg high and Gdeg low cells regarding epithelial-mesenchymal transition-associated factors such as Twist, Slug, Snail, and Vimentin. Moreover, comprehensive microRNA analysis did not reveal a high expression level of miR-200a in Gdeg high cells (data not shown).
DCLK1 has been thoroughly investigated in neuroscience and is vital for neuroblast proliferation, migration, and differentiation [52] . Carla et al. reported that the DCLK1 gene is an attractive molecular target for neuroblastoma therapy [53] . DCLK1 plays a biological role in gastrointestinal tumors, and small molecule inhibitors of DCLK1 may be useful as anti-tumor stem cell drugs in these tumors [54] [55] [56] . Despite clinical trials of new therapies, no significant improvements in pancreatic cancer treatments have occurred. A new strategy, neoadjuvant chemotherapy, has been used to control local invasion and early micrometastasis before surgery. In the present study, we found high expression levels of DCLK1 in clinical samples from two different types of metastatic tumors (liver and lung). DCLK1 may be an essential factor in invasion and metastatic mechanisms and therefore could be a promising therapeutic target for treatment of pancreatic cancer.
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